Monensin sodium salt

Hazard statements (CLP)

H300, H319, H373, H411

Code

Statements

H300

Fatal if swallowed

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Acute toxicity, (Category 2) H300: Fatal if swallowed. Eye irritation, (Category 2) H319: Causes serious eye irritation. Specific target organ toxicity - H373: May cause damage to organs repeated exposure, (Category 2), through prolonged or repeated exposure. Heart, muscle Long-term (chronic) aquatic H411: Toxic to aquatic life with long lasting hazard, (Category 2) effects.

2.2 Label elements

Labelling

Signal word

Danger Danger

Hazard statements

H300 Fatal if swallowed. H319 Causes serious eye irritation. H373 May cause damage to organs (Heart, muscle) through prolonged or repeated exposure. H411 Toxic to aquatic life with long lasting effects. Reduced Labeling (<= 125 ml) H300 Fatal if swallowed.

Precautionary statements

P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P273 Avoid release to the environment. P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P314 Get medical advice/ attention if you feel unwell. P264 Wash skin thoroughly after handling. P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER/ doctor.

Supplemental label elements

none none

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

ECOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

TOXICOLOGICAL INFORMATION

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.